Publish in this journal
Journal Information
Vol. 17. Issue 7.
Pages 376-379 (August - September 2021)
Share
Share
Download PDF
More article options
ePub
Visits
...
Vol. 17. Issue 7.
Pages 376-379 (August - September 2021)
Brief Report
DOI: 10.1016/j.reumae.2019.11.007
Association of Anti-Saccharomyces cerevisiae antibodies with clinical phenotype in spondyloarthritis patients
Asociación de anticuerpos anti-Saccharomyces cerevisiae con fenotipo clínico en pacientes con espondiloartritis
Visits
...
Raquel Miriam Ferreira
Corresponding author
rakelmiriam@gmail.com

Corresponding author.
, Sofia Pimenta, Miguel Bernardes, Lúcia Costa
Department of Rheumatology, São João Hospital Centre, Oporto, Portugal
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (2)
Table 1. Demographic, clinical and immunological characteristics of the 231 SpA patients included. Abbreviations: ASCA – anti-Saccharomyces cerevisiae antibodies; IBD – inflammatory bowel disease; Ig – immunoglobulin. Superscript a: Give some missing data concerning HLA-B27 status since its presence is not mandatory for the diagnosis of SpA and taking into account that this is an observational study, the prevalence was adjusted for patients who had HLA-B27 determination.
Table 2. Clinical characteristics of the SpA patients according to ASCA status. Abbreviations: ASCA – anti-Saccharomyces cerevisiae antibodies; IBD – inflammatory bowel disease; SD – standard deviation.
Show moreShow less
Abstract
Introduction

The association between spondyloarthritis (SpA) and inflammatory bowel disease (IBD) has been shown in many studies. More recently, with the hypothesis that increased gut inflammation is of etiopathogenic importance in the development of SpA, evaluation of anti-Saccharomyces cerevisiae antibodies (ASCA) has gained increasing relevance.

Objective

To study the status and frequency of ASCA in SpA patients and the association of these biomarkers with the clinical profile.

Methods

An observational study was performed including 231 SpA patients treated with biologic therapy. ASCA IgA and IgG levels were determined by micro-enzyme-linked immunosorbent assay.

Results

Our data showed an increase of ASCA IgA positivity among SpA patients. No relationship was found between ASCA status and the demographic aspects, genetic factors or clinical presentation, except for the association with IBD.

Conclusion

Our study confirms that ASCA IgA are elevated in SpA patients. Although there was no evidence of association with a particular disease phenotype, the existence of higher ASCA levels sustains a close relationship between gut and SpA.

Keywords:
Anti-Saccharomyces cerevisiae antibodies
Spondylarthritis
Inflammatory bowel disease
Biomarkers
Resumen
Introducción

La asociación entre la espondiloartritis (SpA) y la enfermedad inflamatoria intestinal (EII) se ha demostrado en muchos estudios. Recientemente, con la hipótesis de que el aumento de la inflamación intestinal es de importancia etiopatogénica en el desarrollo de la SpA, la evaluación de los anticuerpos anti-Saccharomyces cerevisiae (ASCA) ha adquirido una relevancia creciente.

Objetivo

Estudiar los niveles de los ASCA en pacientes con SpA, y la asociación de estos biomarcadores con el perfil clínico.

Métodos

Se realizó un estudio observacional que incluyó a 231 pacientes con SpA tratados con terapia biológica. Los niveles de ASCA IgA e IgG se determinaron por técnica de ensayo de inmunoabsorción ligado a enzimas.

Resultados

Nuestros datos mostraron un aumento de la positividad de ASCA IgA entre los pacientes con SpA. No se encontró ninguna relación entre los ASCA y los aspectos demográficos, factores genéticos o presentación clínica, excepto la asociación con la EII.

Conclusión

Nuestro estudio confirma que los niveles de ASCA IgA están elevados en pacientes con SpA. Aunque no hubo evidencia de asociación con un fenotipo de enfermedad en particular, la existencia de niveles más altos de ASCA mantiene una relación estrecha entre el intestino y la SpA.

Palabras clave:
Anticuerpos anti-Saccharomyces cerevisiae
Espondiloartritis
Enfermedad inflamatoria intestinal
Biomarcadores

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Reumatología Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?